Current Report Filing (8-k)
June 27 2018 - 5:23PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 26, 2018
RITTER
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or other
jurisdiction
of incorporation)
|
|
001-37428
(Commission
File
Number)
|
|
26-3474527
(I.R.S.
Employer
Identification
No.)
|
1880
Century Park East, Suite 1000
|
|
|
Los
Angeles, California
|
|
90067
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(310) 203-1000
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 5.07.
Submission of Matters to a Vote of Security Holders.
The
annual meeting of stockholders (the “Annual Meeting”) of Ritter Pharmaceuticals, Inc. (the “Company”)
was held on June 26, 2018. At the Annual Meeting, the Company’s stockholders voted on the following two proposals and cast
their votes as described below.
Proposal
1—Election of Directors
Each
of the seven nominees for election to the board of directors was elected to hold office for a one-year term and until their respective
successors are elected and qualified by the following votes:
Name
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
Noah Doyle
|
|
|
1,229,081
|
|
|
|
10,900
|
|
|
|
1,888,760
|
|
Matthew W. Foehr
|
|
|
1,230,851
|
|
|
|
9,130
|
|
|
|
1,888,760
|
|
Paul V. Maier
|
|
|
1,230,852
|
|
|
|
9,129
|
|
|
|
1,888,760
|
|
Dr. William M. Merino
|
|
|
1,231,078
|
|
|
|
8,903
|
|
|
|
1,888,760
|
|
Andrew J. Ritter
|
|
|
1,231,304
|
|
|
|
8,677
|
|
|
|
1,888,760
|
|
Ira E. Ritter
|
|
|
1,231,909
|
|
|
|
8,072
|
|
|
|
1,888,760
|
|
Michael D. Step
|
|
|
1,231,054
|
|
|
|
9,927
|
|
|
|
1,888,760
|
|
Proposal
2—Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm
The
ratification of the appointment by the Audit Committee of the board of directors of Mayer Hoffman McCann P.C. as the independent
registered public accounting firm of the Company for the fiscal year ending December 31, 2018 was approved by the following vote:
For:
|
3,062,335
|
Against:
|
38,742
|
Abstained:
|
27,664
|
Broker
Non-Votes:
|
—
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
RITTER PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Andrew J. Ritter
|
|
Name:
|
Andrew J. Ritter
|
|
Title:
|
Chief Executive Officer
|
Date:
June 27, 2018
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Apr 2023 to Apr 2024